Perspective Therapeutics (CATX) Interest Expenses (2010 - 2026)

Perspective Therapeutics has disclosed Interest Expenses across 11 years of filings, most recently posting $105000.0 for Q1 2026.

• Interest Expenses for Q1 2026 came in at $105000.0, down 17.97% year-over-year; the trailing twelve-month figure through Mar 2026 was $353000.0 (up 140.14% YoY), and the FY2025 annual result was $376000.0, up 683.33% from the prior year.
• Interest Expenses came in at $105000.0 for Q1 2026 at Perspective Therapeutics, up from $64000.0 in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $128000.0 in Q1 2025 to a low of -$73000.0 in Q4 2024.
• The 4-year median for Interest Expenses is $29000.0 (2024), against an average of $47000.0.
• Across the five-year window, Interest Expenses slumped 404.17% in 2024 and surged 417.39% in 2025, its largest moves.
• Perspective Therapeutics' Interest Expenses stood at $24000.0 in 2023, then plunged by 404.17% to -$73000.0 in 2024, then surged by 187.67% to $64000.0 in 2025, then surged by 64.06% to $105000.0 in 2026.
• The last three Interest Expenses figures came in at $105000.0 (Q1 2026), $64000.0 (Q4 2025), and $65000.0 (Q3 2025), per Business Quant data.